![](/img/cover-not-exists.png)
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
Samir D. Undevia, Nicholas J. Vogelzang, Ann M. Mauer, Linda Janisch, Sridhar Mani, Mark J. RatainVolume:
22
Language:
english
Pages:
10
DOI:
10.1023/b:drug.0000036687.26604.8c
Date:
November, 2004
File:
PDF, 147 KB
english, 2004